🔗 Share this article

While the United States continues making unprecedented adjustments to its immunization schedules, an unexpected name appears somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about coronavirus vaccinations throughout the global health crisis and has concentrated on alleged deaths following Covid immunization in her short position at the Food and Drug Administration.

Planned Changes to Pediatric Immunization Program

Public health authorities planned to reveal sweeping changes to the pediatric vaccination calendar in December, bringing the US with the Danish vaccine program, it is understood – a major change that would place the US out of step with much of the world with little proof for improved outcomes. This reveal has been pushed back until the coming year.

Rather than the director of the vaccine center, Høeg is set to address the audience at the gathering. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the division this year.

A New Direction at the Regulatory Body

This interim role might represent a tighter collaboration between the drug and biologics centers as Dr. Høeg and Prasad solidify control at the regulatory agency – and it suggests a greater focus upon rolling back previously authorized immunizations at the FDA.

Høeg has repeatedly called for ending some pediatric vaccine recommendations in the US to become more similar to Denmark, a society with comprehensive healthcare and a number of inhabitants approximately the size of the state of Wisconsin.

To date comments, she has persisted in emphasizing on vaccines – traditionally the domain of Dr. Prasad, head of the FDA’s vaccine center – instead of pharmaceutical oversight.

Doubts Over Background

The appointee has no obvious experience in medication creation, approval processes or management, which has been customary for previous directors of the CBER. She has been employed at the FDA as a top consultant to the commissioner and CBER since spring.

“She doesn’t seem to have the necessary background” for overseeing the drug-regulation department, stated a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She lacks experience in managing a large organization. She lacks background in pharmaceutical oversight.”

Former commissioners of the center would “grasp laws and regulations and the underlying principles of drug development”, noted Dr. Janet Woodcock. “Objectively, she lacks the kind of background that former directors who led CBER have had.”

CDER has an vast portfolio at the agency, Woodcock stated.

“The public just zeroes in on the innovative therapies, but the generic program authorizes numerous generic medications. There’s a biosimilars division, OTC medication office and more, and each of these need to be supervised,” Dr. Woodcock noted. “The thing you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

There is also, a substantial leadership component to the role, which oversees over 5,000 personnel. “It is a huge leadership role, if you do it right,” Woodcock concluded.

Agency Reaction and Contentious Initiatives

When asked about concerns about Høeg’s credentials and whether this selection signifies greater collaboration among regulatory chiefs on immunizations, a spokesperson said that the “concerns stem from incorrect premises”.

“Her resume aligns with the duties of her job,” the official explained, citing the months Dr. Høeg spent guiding the agency head on “drug safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg inherits the agency head's controversial priority voucher program, a contentious rapid medication authorization process that apparently troubled her preceding directors. “By what process are these medications being picked for this voucher program? Who takes the choices?” Dr. Howard asked. “There’s a lot of lack of transparency going on at the FDA right now.”

Overall, he said, “the agency seems to be moving towards more relaxed oversight of most medications, aside from immunizations.”

Public Track Record on Immunizations

Concerning vaccines, Høeg has a clearer, if problematic, past, Howard have noted. She released a study using non-validated public submissions to assess the frequency of heart inflammation following Covid immunization. She consulted for the state of Florida surgeon general Joseph Ladapo, who reportedly have changed statistics to suggest Covid vaccinations are more dangerous than they are.

Among her “desired changes” for the incoming government featured revising rules for new vaccines and halting “unnecessary” vaccines, she remarked post-election on a podcast. At the FDA, Dr. Høeg has reportedly floated the idea of preventing teenage boys from receiving Covid vaccines.

“She is an thorough dogmatist who begins with her preconceived notions and reverse-engineers to accommodate the science in a very misleading, untruthful fashion,” Howard argued.

Gaining Influence and a “Push for Payback”

Dr. Høeg joined other dissenters, {like|